| Name | Alizapride hydrochloride |
| Description | Alizapride hydrochloride (Alizapride HCl) is a dopamine receptor antagonist used for the treatment of nausea and vomiting. |
| In vitro | Intravenous administration of 5 mg/kg Alizapride in rats effectively counteracts the reduction in gastrointestinal motility induced by the given dose of Apomorphine. Alizapride exhibits low toxicity in mice and rats, particularly when administered extragastrically. Following oral or extragastric administration, Alizapride is primarily excreted in its unmodified form; however, approximately 25% of Alizapride undergoes metabolic transformation before excretion. |
| In vivo | Alizapride contains an N-allyl moiety, which may undergo N-deallylation and/or epoxidation, potentially leading to the formation of chemically reactive metabolites. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 50 mg/mL (142.11 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 40 mg/mL (113.69 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | DopamineReceptor | Dopamine Receptor | Dopamine | Alizapride Hydrochloride | Alizapride hydrochloride | Alizapride |
| Inhibitors Related | Olanzapine | Clozapine N-Oxide | Mirtazapine | Octopamine hydrochloride | Benserazide hydrochloride | L-DOPA | Octodrine | Citicoline | Phenothiazine | Oxolinic acid | Mianserin hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Obesity Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |